Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Evaluating the current data for CDK4/6 inhibition in resistant prostate cancer

Kevin Zarrabi • 29 May 2026
ASCO 2026
Genitourinary Cancer Prostate Cancer
RiboX

Kevin Zarrabi, MD, MS, FACP, Thomas Jefferson University, Philadelphia, PA, briefly discusses the potential role of CDK4/6 inhibition in the current treatment paradigm for antigen pathway modulation-resistant prostate cancer, noting that the absence of an efficacy signal does not currently support its use. However, ongoing biomarker research may help identify patient subsets that could benefit from targeting this pathway in the future. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Zarrabi

Evaluating adverse events after T-cell redirecting therapies in prostate cancer
2:03
Evaluating adverse events after T-cell redirecting therapies in prostate cancer
Kevin Zarrabi • 29 May 2026
RiboX: enzalutamide with or without ribociclib in RB-positive mCRPC
2:18
RiboX: enzalutamide with or without ribociclib in RB-positive mCRPC
Kevin Zarrabi • 29 May 2026
Advances in T-cell redirecting therapies for prostate cancer
0:53
Advances in T-cell redirecting therapies for prostate cancer
Kevin Zarrabi • 24 Apr 2026
Combining 177Lu-PSMA-617 with T-cell engagers in prostate cancer
0:41
Combining 177Lu-PSMA-617 with T-cell engagers in prostate cancer
Kevin Zarrabi • 24 Apr 2026

Related Videos

New approaches to curing bladder and kidney cancers: where do we stand?
3:07
New approaches to curing bladder and kidney cancers: where do we stand?
Srikala Sridhar • 30 May 2026
Predictive biomarkers in bladder & kidney cancer: insights into recent progress
0:33
Predictive biomarkers in bladder & kidney cancer: insights into recent progress
Srikala Sridhar • 30 May 2026
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
2:13
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
Joaquim Bellmunt • 30 May 2026
ctDNA-guided therapy: transforming treatment decisions across tumor types
1:20
ctDNA-guided therapy: transforming treatment decisions across tumor types
Joaquim Bellmunt • 30 May 2026
The content of VJOncology is intended for healthcare professionals